Description:
A drug used to treat adults with squamous cell carcinoma of the esophagus that cannot be removed by surgery or has spread to other parts of the body. It is used in patients whose cancer was treated with systemic therapy that did not include a PD-1 inhibitor or PD-L1 inhibitor. It is also being studied in the treatment of other types of cancer. Tevimbra binds to a protein called PD-1, which is found on T cells (a type of immune cell). Blocking this protein may help the immune system kill cancer cells. Tevimbra is a type of monoclonal antibody and a type of immune checkpoint inhibitor. Also called tislelizumab.
